Trial reportHaematologica2018
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis.Annals of hematology · 2025Pooled it
- Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.Current oncology (Toronto, Ont.) · 2018Guideline
- Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia.Scientific reports · 2025Trial
- Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.Investigational new drugs · 2022Trial
- Trial
- Trial
- Developing MRD as an early endpoint for accelerated approval in CLL.Seminars in hematology · 2025Review
- Rare dermatomuscular manifestations in a patient with small lymphocytic lymphoma: A case report.Experimental and therapeutic medicine · 2025Article
- Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis.Therapeutic advances in medical oncology · 2024Article
- Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia.Therapeutic advances in medical oncology · 2024Article
- Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.Investigational new drugs · 2023Article
- Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.Clinical and translational science · 2023Article
- Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?Blood advances · 2021Article
- Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.Leukemia · 2021Review
- Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).Haematologica · 2021Article
- Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review.Journal of clinical medicine · 2021Review
- Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?Cancers · 2021Review
- Current Treatment Options in CLL.Cancers · 2021Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 14 institutions in 9 countries.
Funding
Abstract
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus chlorambucil-treated patients without a complete response after Cycle 6 received chlorambucil monotherapy for at least six additional cycles or until complete response. The primary endpoint was complete response rate (confirmed by bone marrow biopsy) after Cycle 6 in first-line patients. Secondary endpoints included progression-free survival, overall survival, minimal residual disease, and safety. Overall, 357 patients were randomized (rituximab plus bendamustine, n=178; rituximab plus chlorambucil, n=179; intent-to-treat population), including 241 first-line patients (n=121 and n=120, respectively); 355 patients received treatment (n=177 and n=178, respectively; safety population). In first-line patients, complete response rate after Cycle 6 (rituximab plus bendamustine, 24%; rituximab plus chlorambucil, 9%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.